

HALOZYME THERAPEUTICS INC

Form 8-K/A

January 07, 2015

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 8-K/A

---

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

January 7, 2015

---

HALOZYME THERAPEUTICS, INC.  
(Exact name of registrant as specified in its charter)

---

Delaware  
(State or other jurisdiction  
of incorporation)

001-32335  
(Commission  
File Number)

88-0488686  
(IRS Employer  
Identification No.)

11388 Sorrento Valley Road, San Diego, California  
(Address of principal executive offices)

92121  
(Zip Code)

Registrant's telephone number, including area code:

(858) 794-8889

Not Applicable

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 2.02 Results of Operations and Financial Condition.

On January 7, 2015, Halozyme, Therapeutics, Inc. (“Halozyme”) issued a press release containing information concerning its cash, cash equivalents and marketable securities (unaudited) at December 31, 2014. A copy of that press release is being furnished as Exhibit 99.1.

Item 7.01 Regulation FD Disclosure.

Attached hereto as Exhibits 99.1 and 99.2, which are incorporated herein by reference, are copies of the press release and certain slides used by Halozyme in making an investor presentation and that are expected to be used in subsequent presentations to interested parties, including analysts and stockholders.

This information is being furnished pursuant to Items 2.02 and 7.01 of this Report and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by Halozyme, under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference. This Report will not be deemed an admission as to the materiality of any information in this Report that is being disclosed pursuant to Regulation FD.

Please refer to page 2 of Exhibit 99.2 for a discussion of certain forward-looking statements included therein and the risks and uncertainties related thereto.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 Press release, dated January 7, 2015\*

99.2 Halozyme Therapeutics, Inc. Investor Presentation, dated January 2015\*

---

\* Previously submitted.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

January 7, 2015

HALOZYME THERAPEUTICS, INC.

By: /s/ David Ramsay

Name: David Ramsay

Title: Vice President and Chief Financial Officer